Fulcrum Therapeutics (FULC) Competitor Comparison
We are evaluating the key criteria listed to compare Fulcrum Therapeutics (FULC) against its competitors in the Biotechnology industry.
Market Capitalization
158 / 368Gross Profits
215 / 278Total Revenue
218 / 300EBITDA
214 / 337Free Cashflow
224 / 352Quick Ratio
32 / 357Earnings per Share
69 / 359Dividend yield
0 / 6Total Cash
127 / 358Performance 3 years
254 / 368Performance 5 years
175 / 368Performance 10 years
193 / 368Linearity 3 years
193 / 368Linearity 5 years
68 / 368Linearity 10 years
106 / 368Total Rank
131 / 368Dividend Rank
135 / 368Valuation Rank
155 / 368Piotroski Rank
280 / 368Muliplier Rank
347 / 368Performance 10 years - FULC ranking 193 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.